Navigation Links
FASEB announces 2014 Science Research Conference: Folic Acid, Vitamin B12 and One Carbon Metabolism

Bethesda, MD This 2014 FASEB Science Research Conference focuses on recent advances in the study of folate, vitamin B12 (cobalamin), methionine and sulfur amino acid metabolism as they pertain to the fields of nutrition, public health and policy, genetics, basic biology and clinical medicine.

This long-standing inter-disciplinary conference held every two years since 1986, attracts a wide variety of attendees: physician-scientists, basic scientists, population geneticists, epidemiologists, nutritionists and representatives from national and international nutritional and public health monitoring agencies. Previous conferences discussed and helped implement important policies such as the Folate Food Fortification which was then enacted in the United States and Canada.

New exciting aspects of methionine metabolism such as the new role of hydrogen sulfide as the third gaseous messenger, and study of the genetics and metabolomics of folate and cobalamin-dependent pathways which are yielding insights into obesity, cancer, liver and cognitive diseases will be included in the up-coming meeting. The meeting is also an excellent opportunity for more junior scientists, and graduate and students to present oral abstracts and posters and meet on an informal basis and discuss their research with the leaders in this specialized area of biology and metabolism.


Contact: Robin Crawford
Federation of American Societies for Experimental Biology

Page: 1

Related biology news :

1. FASEB 2013 Excellence in Science Award recipient announced
2. Undergraduate Student Summer Research Award recipients announced for the 2012 FASEB MARC summer research opportunity program
3. FASEB lauds Air India for transporting research animals
4. FASEB urges biomedical research community to speak out against sequestration
5. FASEB SRC announces conference: Gastrointestinal Tract XV: Epithelia, Microbes, Inflammation & Cancer
6. FASEB SRC announces conference registration open: The Biology of Calpains in Health and Disease
7. FASEB SRC announces: Mechanism and Regulation of Prokaryotic Transcription Conference
8. FASEB SRC announces conference: Renal Hemodynamics: Integrating with the Nephron & Beyond
9. FASEB SRC announces conference registration open for: Ciliate Molecular Biology
10. FASEB SRC announces conference registration open for: Mechanisms in Plant Development Conference
11. FASEB SRC announces conference registration open for: Hematologic Malignancies
Post Your Comments:
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 2016 Andrew D ... Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology: